Matt Gline, Roivant CEO (courtesy Roivant)
Roivant's JAK/TYK2 inhibitor fails PhII lupus study
Roivant reported Monday morning that a program licensed from Pfizer failed a Phase II lupus trial and that it would end development in the condition …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.